Role of complement systems in IVIG mediated attenuation of cognitive deterioration in Alzheimer's disease

Current Alzheimer Research

Volumn 11, Issue 7, 2014, Pages 637-644

  Gong, Bing ^a   Levine, Samara ^a   Barnum, Scott R ^b   Pasinetti, Giulio M ^a,c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b University of Alabama at Birmingham   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; Cognitive function; Complement component; Immunotherapy; IVIG; Synaptic plasticity

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMYLOID BETA PROTEIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C5A; CYCLIC AMP; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GANTENERUMAB; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; PROTEIN KINASE C; SOLANEZUMAB; ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; AMPA RECEPTOR; ANAPHYLATOXIN; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C4B BINDING PROTEIN; COMPLEMENT COMPONENT C5A RECEPTOR; COMPLEMENT COMPONENT C5B; COMPLEMENT MEMBRANE ATTACK COMPLEX; MITOGEN ACTIVATED PROTEIN KINASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; STAT3 PROTEIN; COMPLEMENT; IMMUNOLOGIC FACTOR;

ALZHEIMER DISEASE; ARTICLE; COGNITION; COMPLEMENT SYSTEM; DEMENTIA; HUMAN; IMMUNIZATION; MENTAL DETERIORATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SYNAPSE; ATTENUATION; BRAIN FUNCTION; COGNITIVE DEFECT; COMPLEMENT ACTIVATION; DETERIORATION; DOWN REGULATION; HIPPOCAMPAL CA1 REGION; IMMUNE DEFICIENCY; IMMUNOTHERAPY; INNATE IMMUNITY; LONG TERM POTENTIATION; MEMORY CONSOLIDATION; NERVE CELL PLASTICITY; NEUROFIBRILLARY TANGLE; NEUROLOGIC DISEASE; PROTEIN AGGREGATION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SYNAPTIC MEMBRANE; ANIMAL; COGNITION DISORDERS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ALZHEIMER DISEASE; ANIMALS; COGNITION DISORDERS; COMPLEMENT SYSTEM PROTEINS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; RECEPTORS, AMPA; SYNAPSES;

EID: 84906895035     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205011666140812113707     Document Type: Article

References (82)

1. Lobello K, Ryan JM, Liu E, Rippon G, Black R. Targeting Beta amyloid: a clinical review of immunotherapeutic approaches in Alzheimer's disease. Int J Alzheimers Dis 2012: 628070 (2012).
2. Loeffler DA. Intravenous immunoglobulin and Alzheimer's disease: what now? J Neuroinflammation 10(1): 702094-701070 (2013).
3. Magga J, Puli L, Pihlaja R, Kanninen K, Neulamaa S, Malm T, et al. Human intravenous immunoglobulin provides protection against Abeta toxicity by multiple mechanisms in a mouse model of Alzheimer's disease. J Neuroinflammation 7: 90 (2010).
4. Wozniak MA, Itzhaki RF. Intravenous immunoglobulin reduces beta amyloid and abnormal tau formation caused by herpes simplex virus type 1. J Neuroimmunol 257(1-2): 7-12 (2013).
5. Sayah S, Jauneau AC, Patte C, Tonon MC, Vaudry H, Fontaine M. Two different transduction pathways are activated by C3a and C5a anaphylatoxins on astrocytes. Brain Res Mol Brain Res 112(1-2): 53-60 (2003).
6. Dodel R, Rominger A, Bartenstein P, Barkhof F, Blennow K, Forster S, et al. Intravenous immunoglobulin for treatment of mild-tomoderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol 12(3): 233-243 (2013).
7. Gong B, Pan Y, Zhao W, Knable L, Vempati P, Begum S, et al. IVIG immunotherapy protects against synaptic dysfunction in Alzheimer's disease through complement anaphylatoxin C5a-mediated AMPA-pCREB signaling pathway. Mol Immunol 56(4): 619-29 (2013).
8. McGeer EG, McGeer PL. Brain inflammation in Alzheimer disease and the therapeutic implications. Curr Pharm Des 5(10): 821-836 (1999).
9. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 21(3): 383-421 (2000).
10. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimer-diseaselike pathology in the PDAPP mouse. Nature 400(6740): 173-7 (1999).
11. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, et al. Peripherally administered antibodies against amyloid betapeptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6(8): 916-919 (2000).
12. Wyss-Coray T, Mucke L. Inflammation in neurodegenerative disease--a double-edged sword. Neuron 35(3): 419-432 (2002).
13. Abraham CR. Reactive astrocytes and alpha1-antichymotrypsin in Alzheimer's disease. Neurobiol Aging 22(6): 931-936 (2001).
14. Heneka MT, O'Banion MK. Inflammatory processes in Alzheimer's disease. J Neuroimmunol 184(1-2): 69-91 (2007).
15. Pasinetti GM. Inflammatory mechanisms in neurodegeneration and Alzheimer's disease: the role of the complement system. Neurobiol Aging 17(5): 707-716 (1996).
16. Yang L, Lu R, Jiang L, Liu Z, Peng Y. Expression and genetic analysis of tumor necrosis factor-alpha (TNF-alpha) G-308A polymorphism in sporadic Alzheimer's disease in a Southern China population. Brain Res 1247: 178-181 (2009).
17. Bellander BM, Singhrao SK, Ohlsson M, Mattsson P, Svensson M. Complement activation in the human brain after traumatic head injury. J Neurotrauma 18(12): 1295-1311 (2001).
18. van Beek J, Elward K, Gasque P. Activation of complement in the central nervous system: roles in neurodegeneration and neuroprotection. Ann NY Acad Sci 1992: 56-71 (2003).
19. Guo RF, Ward PA. Role of C5a in inflammatory responses. Annu Rev Immunol 23: 821-852 (2005).
20. Bradt BM, Kolb WP, Cooper NR. Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide. J Exp Med 188(3): 431-438 (1998).
21. Dunkelberger JR, Song WC. Complement and its role in innate and adaptive immune responses. Cell Res 20(1): 34-50 (2010).
22. Huber-Lang M, Sarma JV, Zetoune FS, Rittirsch D, Neff TA, McGuire SR, et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 12(6): 682-687 (2006).
23. Gerard NP, Bao L, Xiao-Ping H, Eddy RL,Jr, Shows TB, Gerard C. Human chemotaxis receptor genes cluster at 19q13.3-13.4. Characterization of the human C5a receptor gene. Biochemistry 32(5): 1243-1250 (1993).
24. Humayun S, Gohar M, Volkening K, Moisse K, Leystra-Lantz C, Mepham J, et al. The complement factor C5a receptor is upregulated in NFL-/ mouse motor neurons. J Neuroimmunol 210(1-2): 52-62 (2009).
25. Reines SA, Block GA, Morris JC, Liu G, Nessly ML, Lines CR, et al. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 62(1): 66-71 (2004).
26. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 289(21): 2819-2826 (2003).
27. O'Barr SA, Caguioa J, Gruol D, Perkins G, Ember JA, Hugli T, et al. Neuronal expression of a functional receptor for the C5a complement activation fragment. J Immunol 166(6): 4154-4162 (2001).
28. Tocco G, Musleh W, Sakhi S, Schreiber SS, Baudry M, Pasinetti GM. Complement and glutamate neurotoxicity. Genotypic influences of C5 in a mouse model of hippocampal neurodegeneration. Mol Chem Neuropathol 31(3): 289-300 (1997).
29. Katsel P, Tan W, Haroutunian V. Gain in brain immunity in the oldest-old differentiates cognitively normal from demented individuals. PLoS One 4(10): e7642 (2009).
30. Haroutunian V, Katsel P, Schmeidler J. Transcriptional vulnerability of brain regions in Alzheimer's disease and dementia. Neurobiol Aging 30(4): 561-573 (2009).
31. Lucin KM, Wyss-Coray T. Immune activation in brain aging and neurodegeneration: too much or too little? Neuron 64(1): 110-122 (2009).
32. Mukherjee P, Pasinetti GM. The role of complement anaphylatoxin C5a in neurodegeneration: implications in Alzheimer's disease. J Neuroimmunol 105(2):124-130 (2000).
33. Mukherjee P, Pasinetti GM. Complement anaphylatoxin C5a neuroprotects through mitogen-activated protein kinase-dependent inhibition of caspase 3. J Neurochem 77(1): 43-49 (2001).
34. Osaka H, Mukherjee P, Aisen PS, Pasinetti GM. Complementderived anaphylatoxin C5a protects against glutamate-mediated neurotoxicity. J Cell Biochem 73(3): 303-311 (1999).
35. Mukherjee P, Thomas S, Pasinetti GM. Complement anaphylatoxin C5a neuroprotects through regulation of glutamate receptor subunit 2 in vitro and in vivo. J Neuroinflammation 5: 5 (2008).
36. van Beek J, Nicole O, Ali C, Ischenko A, MacKenzie ET, Buisson A, et al. Complement anaphylatoxin C3a is selectively protective against NMDA-induced neuronal cell death. Neuroreport 12(2): 289-293 (2001).
37. Park H, Poo MM. Neurotrophin regulation of neural circuit development and function. Nat Rev Neurosci 14(1): 7-23 (2013).
38. Mollnes TE, Hogasen K, De Carolis C, Vaquero E, Nielsen EW, Fontana L, et al. High-dose intravenous immunoglobulin treatment activates complement in vivo. Scand J Immunol 48(3): 312-317 (1998).
39. Gong B, Cao Z, Zheng P, Vitolo OV, Liu S, Staniszewski A, et al. Ubiquitin Hydrolase Uch-L1 Rescues beta-Amyloid-Induced Decreases in Synaptic Function and Contextual Memory. Cell 126(4): 775-88 (2006).
40. Gong B, Pan Y, Vempati P, Zhao W, Knable L, Ho L, et al. Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-gamma coactivator 1alpha regulated beta-secretase 1 degradation and mitochondrial gene expression in Alzheimer's mouse models. Neurobiol Aging 34(6):1581-1588 (2013).
41. Ninan I, Arancio O. Presynaptic CaMKII Is Necessary for Synaptic Plasticity in Cultured Hippocampal Neurons. Neuron 42(1): 129-41 (2004).
42. ] Pugazhenthi S, Wang M, Pham S, Sze CI, Eckman CB. Downregulation of CREB expression in Alzheimer's brain and in Abetatreated rat hippocampal neurons. Mol Neurodegener 6: 60 (2011).
43. Stevens CF. CREB and memory consolidation. Neuron 13(4): 769-770 (1994).
44. Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C, et al. Age, neuropathology, and dementia. N Engl J Med 360(22): 2302-2309 (2009).
45. Gong B, Vitolo OV, Trinchese F, Liu S, Shelanski M, Arancio O. Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. J Clin Invest 114(11):1624-1634 (2004).
46. Bito H, Deisseroth K, Tsien RW. CREB phosphorylation and dephosphorylation: a Ca(2+) and stimulus duration-dependent switch for hippocampal gene expression. Cell 87(7): 1203-14(1996).
47. Rothermel E, Zwirner J, Vogt T, Rabini S, Gotze O. Molecular cloning and expression of the functional rat C5a receptor. Mol Immunol 34(12-13): 877-886 (1997).
48. Farkas I, Takahashi M, Fukuda A, Yamamoto N, Akatsu H, Baranyi L, et al. Complement C5a receptor-mediated signaling may be involved in neurodegeneration in Alzheimer's disease. J Immunol 170(11): 5764-5771 (2003).
49. Yin JC, Tully T. CREB and the formation of long-term memory. Curr Opin Neurobiol 6(2): 264-268 (1996).
50. Alberini CM. Transcription factors in long-term memory and synaptic plasticity. Physiol Rev 89(1): 121-145 (2009).
51. Silva AJ, Kogan JH, Frankland PW, Kida S. CREB and memory. Annu Rev Neurosci 21: 127-48 (1998).
52. Johannessen M, Delghandi MP, Moens U. What turns CREB on? Cell Signal 16(11):1211-1227 (2004).
53. Thomas GM, Huganir RL. MAPK cascade signalling and synaptic plasticity. Nat Rev Neurosci 5(3): 173-183 (2004).
54. Schmitt JM, Guire ES, Saneyoshi T, Soderling TR. Calmodulindependent kinase kinase/calmodulin kinase I activity gates extracellular-regulated kinase-dependent long-term potentiation. J Neurosci 25(5):1281-1290 (2005).
55. Wayman GA, Impey S, Marks D, Saneyoshi T, Grant WF, Derkach V, et al. Activity-dependent dendritic arborization mediated by CaM-kinase I activation and enhanced CREB-dependent transcription of Wnt-2. Neuron 50(6): 897-909 (2006).
56. Doong H, Rizzo K, Fang S, Kulpa V, Weissman AM, Kohn EC. CAIR-1/BAG-3 abrogates heat shock protein-70 chaperone complex-mediated protein degradation: accumulation of polyubiquitinated Hsp90 client proteins. J Biol Chem 278(31): 28490-28500 (2003).
57. Gerlo S, Verdood P, Hooghe-Peters EL, Kooijman R. Multiple, PKA-dependent and PKA-independent, signals are involved in cAMP-induced PRL expression in the eosinophilic cell line Eol-1. Cell Signal 17(7): 901-909 (2005).
58. Mao LM, Zhang GC, Liu XY, Fibuch EE, Wang JQ. Group I metabotropic glutamate receptor-mediated gene expression in striatal neurons. Neurochem Res 33(10): 1920-1924 (2008).
59. Chapman PF, White GL, Jones MW, Cooper-Blacketer D, Marshall VJ, Irizarry M, et al. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci 2(3): 271-6 (1999).
60. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative memory deficits, Ab elevation, and amyloid plaques in transgenic mice. Science 274(5284): 99-103 (1996).
61. Humeau Y, Reisel D, Johnson AW, Borchardt T, Jensen V, Gebhardt C, et al. A pathway-specific function for different AMPA receptor subunits in amygdala long-term potentiation and fear conditioning. J Neurosci 27(41):10947-10956 (2007).
62. Malinow R, Malenka RC. AMPA receptor trafficking and synaptic plasticity. Annu Rev Neurosci 25:103-126 (2002).
63. Turner MW. 90 Years On: a Therapy to 'Stimulate the Phagocytes'? Scand J Immunol 48(2):124-126 (1998).
64. Dodel R, Neff F, Noelker C, Pul R, Du Y, Bacher M, et al. Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence. Drugs 70(5): 513-528 (2010).
65. Gong B, Leznik E. The role of ubiquitin C-terminal hydrolase L1 in neurodegenerative disorders. Drug News Perspect 20(6): 365-370 (2007).
66. Menniti FS, Faraci WS, Schmidt CJ. Phosphodiesterases in the CNS: targets for drug development. Nat Rev Drug Discov 5(8): 660-670 (2006).
67. Wright SE, Shaikh ZH, Castillo-Lugo JA, Tanriover B. Aseptic meningitis and abducens nerve palsy as a serious side effect of high dose intravenous immunoglobulin used in a patient with renal transplantation. Transpl Infect Dis 10(4): 294-297 (2008).
68. Takahashi T, Ono S, Ogawa K, Tamura M, Mizutani T. A case of anaphylactoid shock occurring immediately after the initiation of second intravenous administration of high-dose immunoglobulin (IVIg) in a patient with Crow-Fukase syndrome. Rinsho Shinkeigaku 43(6): 350-355 (2003).
69. Duhem C, Dicato MA, Ries F. Side-effects of intravenous immune globulins. Clin Exp Immunol 97(1): 79-83 (1994).
70. Kurz A, Perneczky R. Amyloid Clearance as a Treatment Target Against Alzheimer's Disease. J Alzheimers Dis 24(2): 61-73 (2011).
71. Kawas CH. The oldest old and the 90+ Study. Alzheimers Dement 4(1): S56-9 (2008).
72. Prohovnik I, Perl DP, Davis KL, Libow L, Lesser G, Haroutunian V. Dissociation of neuropathology from severity of dementia in late-onset Alzheimer disease. Neurology 66(1): 49-55 (2006).
73. Oliveira TG, Chan RB, Tian H, Laredo M, Shui G, Staniszewski A, et al. Phospholipase d2 ablation ameliorates Alzheimer's diseaselinked synaptic dysfunction and cognitive deficits. J Neurosci 30(49):16419-16428 (2010).
74. Dalakas MC. Role of IVIg in autoimmune, neuroinflammatory and neurodegenerative disorders of the central nervous system: present and future prospects. J Neurol 253(5): V25-32 (2006).
75. Southwell AL, Patterson PH. Antibody therapy in neurodegenerative disease. Rev Neurosci 21(4): 273-287 (2010).
76. Gong B, Chen F, Pan Y, Arrieta-Cruz I, Yoshida Y, Haroutunian V, et al. SCFFbx2-E3-ligase-mediated degradation of BACE1 attenuates Alzheimer's disease amyloidosis and improves synaptic function. Aging Cell 9(6): 1018-1031 (2010).
77. St-Amour I, Paré I, Tremblay C, Coulombe K, Bazin R and Calon F. IVIG protects the 3xTg-AD mouse model of Alzheimer's disease from memory deficit and A pathology. J Neuroinflammation 11: 54 (2014).
78. Karran E, Hardy J. A Critique of the Drug Discovery and Phase 3 Clinical Programmes targeting the Amyloid Hypothesis for Alzheimer's disease Ann Neurol. 2014 May 23. doi: 10.1002/ana.24188. [Epub ahead of print].
79. Farlow M, Arnold SE, Van Dyck CH, Aisen PS, Snider BJ, Porsteinsson AP, et al. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimer's Dement 8: 261-271 (2012).
80. Bohrmann B, Baumann K, Benz J, Gerber F, Huber W, Knoflach F, et al. Gantenerumab: a novel human anti-Aß antibody demonstrates sustained cerebral amyloid-ß binding and elicits cellmediated removal of human amyloid-ß. J Alzheimers Disease 28: 49-69 (2012).
81. Puli L, Pomeshchik Y, Olas K, Malm T, Koistinaho J, Tanila H. Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer's disease. J Neuroinflammation 9: 105 (2012).
82. Mullane K, Williams M. Alzheimer's Therapeutics: Continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond? Biochem Pharmacol 85: 289-305 (2012).